Larazotide vs Ovagen
A side-by-side research comparison of Larazotide and Ovagen across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Larazotide | Ovagen |
|---|---|---|
| Full name | Larazotide Acetate (AT-1001) | Ovagen (Liver & GI Peptide Bioregulator) |
| Category | Gut Health | Gut Health |
| Status | Investigational (Phase 3) | Research compound (peptide bioregulator) |
| Mechanism | Acts as a zonulin peptide antagonist, preventing zonulin-mediated disassembly of tight junction proteins (ZO-1, occludin, claudins). Maintains paracellular barrier integrity without systemic absorption. | As a signal peptide, it is proposed to regulate gene expression in hepatic and gastrointestinal tissue, supporting protein synthesis, detoxification pathways, and gut-associated immune function. |
| Molecular weight | 1026 Da | ~ (short peptide) |
| Half-life | Not systemically absorbed (local GI action) | Short (peptide) |
| Bioavailability | Minimal systemic absorption (acts locally in GI lumen) | Oral (encapsulated) or subcutaneous |
| Typical dose | 0.5-1 mg | ~1-2 capsules/day or short injectable courses |
| Frequency | 3x daily before meals | Once daily |
| Route | Oral capsule | Oral capsule or subcutaneous |
Larazotide reported benefits
- Reduced intestinal permeability
- Decreased GI symptoms
- Tight junction restoration
- Reduced systemic inflammation from gut
- Improved gluten tolerance
Ovagen reported benefits
- Liver function support
- Gastrointestinal tissue support
- Protein synthesis support (proposed)
- Gut-immune resilience
- Short course-based protocol
Related comparisons
Research and educational reference only. Not medical advice.